Cognitive Impairment from Breast Cancer Chemotherapy in the Perspective of Traditional Chinese Medicine

Zhongjia Yi

doi:10.62051/ijphmr.v2n1.18

Authors

Zhongjia Yi

DOI:

https://doi.org/10.62051/ijphmr.v2n1.18

Keywords:

Breast Cancer, Traditional Chinese Medicine, Chemotherapy, Cognitive impairment

Abstract

In recent years, the incidence of breast cancer has been on the rise globally and in China. The conventional treatment methods for breast cancer include surgery, radiotherapy, chemotherapy, endocrine therapy, targeted therapy, traditional Chinese medicine, and other biological immunotherapy. In the treatment of breast cancer, the status of chemotherapy drugs is unshakable, and the related toxic side effects have gradually attracted people's attention. Doxorubicin is an anthracycline drug, which is the cornerstone drug for adjuvant chemotherapy for breast cancer. It exerts anti-tumor effects by inserting DNA and inhibiting topoisomerase II, but it can also cause severe neurotoxicity by crossing the blood-brain barrier, clinically manifested as memory and executive function decline, etc., which has a huge impact on the patient's work and life. With the development of modern medicine, the advantages of traditional Chinese medicine in preventing and treating adverse reactions related to breast cancer and improving patients' quality of life are increasingly being recognized. Traditional Chinese medicine classifies chemotherapy-induced cognitive impairment into related diseases such as "dementia", "brain marrow depletion", and "forgetfulness" based on its main clinical symptoms, and achieves the therapeutic effect of improving chemotherapy-induced cognitive impairment through clinical differentiation and coordinating relevant therapies, providing a scientific basis for the treatment of adverse reactions related to malignant tumors by traditional Chinese medicine in radiotherapy and chemotherapy.

References

[1] Silberfarb PM. Chemotherapy and cognitive defects in cancer patients [J]. Annu Rev Med, 1983, 34:35-46.

[2] ObersteM, SchaffrathN, SchmidtK, etal. Protocol for the “Chemo brain in Motion-study” (CIM-study): AR andomized Placebo-con trolled Trial of the Impact of a High-Intensity Interval Endurance Training on Cancer Related Cognitive Impairments in Women with Breast Cancer Receiving First-line Chemotherapy [J]. BMC Cancer, 2018, 18(1):1071.

[3] SEIGERSR, SCHAGENSB, VANTELLINGENO, etal. Chemotherapy-related cognitive dysfunction:current animals tudies and future directions [J]. Brain imaging and behavior, 2013, 7(4):453-9.

[4] PEDDIPF, PEDDIS, SANTOSES,etal.Central nervous system toxicities of chemotherapeutic agents [J]. Expert review of anti cancer therapy, 2014, 14(7):857-63

[5] AhlesTA. Brain vulnerability to chemotherapy toxicities [J]. sychoon cology, 2012, 21(11): 1141-1158.

[6] KrynetskiyE, KrynetskaiaN, RihawiD, etal. Establishing a model for assessing DNA damage in murine brain cells as a molecular marker of chemotherapy-associated cognitive impairment [J]. LifeSci, 2013, 93(17): 605-610.

[7] AtukerenP, Yavu zB, SoydincHO, etal. Variations in systemic biomarkers of oxidative / nitrosative stress and DNA damage before and during the consequent two cycles of chemotherapy in breast cancer patients [J]. Clin Chem Lab Med, 2010, 48(10):1487-1495.

[8] TanZS, BeiserAS, VasanRS, etal.Inflammatory markers and the risk of Alzheimer disease:the Framingham Study [J]. Neurology, 2007, 68(22):1902-1908.

[9] WangXM, WalittB, SaliganL, etal.Chemobrain:a critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy [J]. Cytokine, 2015, 72(1):86-96.

[10] AndreottiC, RootJC, AhlesTA, etal.Cancer, coping, and cognition:a model for the role of stress reactivity in cancer-related cognitive decline [J]. Psychooncology, 2014, 13(2):195-210

[11] Xiaoqiang Yu. A Study on the Genesis of the "Spirit" Theory in the Huangdi Neijing [D]. Shandong University of Traditional Chinese Medicine, 2012.

[12] Qiongqiong Liu, Hu Qian. An analysis of Psychiatric Disorders in Traditional Chinese Medicine [J]. Bright Chinese Medicine, 2016, 31(11):1521-1523.

[13] Qingren Wang. The Errors in Medicine Explained and Corrected [M]. Shanghai: Science and Technology Press, 1990: 16.

[14] Cheruku Sri Pragnya, Ramalingayya Grandhi Venkata, Chamallamudi Mallikarjuna Rao, Bis-was Subhankar, Nandakumar Krishnadas, Nampoothiri Madhavan, Gourishetti Karthik, Kumar N-itesh. Catechin ameliorates doxorubicin-induced neurona l cytotoxicity in in vitro and epis-odic memory deficit in in vivo in Wistar rat s. [J]. Cytotechnology, 2018, 70(1)

[15] Lucy Player BTeach (Secondary)/BHealth & PhysEd, Lynette Mackenzie PhD, MEdStud BAppSc (OT) DipCOT, Karen Willis PhD, Siew Yim Loh PhD, MScMedEd, BSc ApplRehab. Wom-en's experiences of cognitive changes or ‘chemobrain’ following treatment for breast cancer: A role for occupational therapy? [J]. Australian Occupational Therapy Journal, 2014, 61(4).

[16] Jamie S. Myers. Cancer- and Chemotherapy-Related Cognitive Changes: The Patient Experience [J]. Seminars in Oncology Nursing, 2013, 29(4).

[17] Michelle Lycke, Lies Pottel, Hans Pottel, Lore Ketelaars, Karin Stellamans, Koen Van Eygen, Philippe Vergauwe, Patrick Werbrouck, Laurence Goethals, Patricia Schofield, Tom Boterberg, Ph-ilip R. Debruyne. Predictors of baseline cancer‐related cognitive impairment in cancer p-atients scheduled for a curative treatment [J]. Psycho‐Oncology, 2017, 26(5).

[18] Yanbin Ding. Research on the Intervention of Traditional Chinese Medicine in Cognitive Function Disorders Caused by Chemotherapy for Breast Cancer Patients [D]. Guangzhou University of Chinese Medicine, 2016.

[19] Xue Na, Guowang Yang, and Xiaomin Wang. Current status and considerations of TCM syndrome research in breast cancer. [J]. Chinese Medical Journal, 014, 55(02):168-171.

[20] Yonghou Zhao, Yuping Zhang, Xuelian Lin, Shanshan Bao, Bai Bing. Construction of the Academic System and Development Framework of Traditional Chinese Medicine Psychiatry [J]. Chinese Medical Journal, 2013, 54(15):1267-1272